(MedPage Today) — Obinutuzumab (Gazyva) appears set to add systemic lupus erythematosus (SLE) to its list of approved indications, as results from a phase III trial showed it was significantly more effective than placebo, with no new safety concerns…
Source link : https://www.medpagetoday.com/rheumatology/lupus/120193
Author :
Publish date : 2026-03-06 16:05:00
Copyright for syndicated content belongs to the linked Source.
